These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35771147)

  • 1. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
    Shi R; Zhao H; Zhao S; Yuan H
    Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
    Zhao J; Liu Z; Yang K; Shen S; Peng J
    Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
    Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
    Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
    Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
    Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
    Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.
    Zhang G; Lv X; Yang Q; Liu H
    BMC Cancer; 2022 Aug; 22(1):888. PubMed ID: 35964022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
    Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
    Front Immunol; 2022; 13():966167. PubMed ID: 36304466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.
    Xu W; Nie C; Lv H; Chen B; Wang J; Wang S; Zhao J; He Y; Chen X
    Front Immunol; 2022; 13():1010554. PubMed ID: 36275697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.
    Cai J; Wu S; Zhang F; Dai Z
    Front Immunol; 2022; 13():952413. PubMed ID: 35911718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma.
    Yan Y; Luo YH; Zheng DF; Mu T; Wu ZJ
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):34-45. PubMed ID: 32563589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
    Huang X; Yang C; Wang J; Sun T; Xiong H
    Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer.
    Meng Q; Lu YX; Ruan DY; Yu K; Chen YX; Xiao M; Wang Y; Liu ZX; Xu RH; Ju HQ; Qiu MZ
    Mol Ther Nucleic Acids; 2021 Jun; 24():695-710. PubMed ID: 33996253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
    Chen J; Gingold JA; Su X
    Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.
    Ma P; Zou C; Xia S
    Immunogenetics; 2022 Dec; 74(6):539-557. PubMed ID: 35895154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
    Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.